



Healthscope

31 May 2010

Head Office
Level 1
312 St Kilda Road
Melbourne VIC 3004
PO Box 7586
Melbourne VIC 8004
Ph: +61 3 9926 7500
Fax: +61 3 9926 7599
www.healthscope.com.au

Healthscope receives competitive proposals

Healthscope announced on 20 May 2010 that it had received a revised, indicative, non-binding proposal from a private equity consortium ("the Consortium") to acquire all of the issued capital of Healthscope by scheme of arrangement at a price of \$5.75 per share.

Healthscope further advised that, subject to negotiation of an appropriate confidentiality agreement, the Consortium would be granted the opportunity to conduct due diligence. Healthscope expects to finalise an appropriate confidentiality agreement shortly.

The Company has, since close of trade on Friday 28 May, received two additional indicative and non-binding proposals to acquire all of the issued capital of Healthscope for cash consideration by scheme of arrangement. Both of these proposals were at a price of \$5.80 per share.

The Healthscope Board, together with its advisers, has considered these proposals using the same criteria as it used to assess the Consortium's proposal and has formed the view that each is equal to or superior to the Consortium's proposal. The Board has therefore concluded that these parties will, subject to negotiation of appropriate confidentiality agreements, also be granted the opportunity to conduct due diligence.

The Board considers that at this time the interests of shareholders will be best served by a formal process to thoroughly evaluate whether a change of control offer, at a price and on terms that the Board would recommend, can be secured. In order to ensure that any process operates as quickly and effectively as possible the Board does not intend to make any further announcements unless and until a recommended offer is secured, or unless there is a development which it judges should be disclosed immediately. This process will take several weeks.

Healthscope continues to recommend that shareholders take no action. The due diligence process may or may not result in an offer for the Company or a recommendation by the Board. If it does not, the Board believes that Healthscope has a very attractive independent future and that the Company is well positioned to continue to deliver strong growth.

For further information please contact:

Healthscope Investor Relations:
Caroline Sladen
(03) 9926 7848

Media Communications:
nightingale communications
Kate Inverarity
0413 163 020

Lisa Keenan
0409 150 771